Copyright
©The Author(s) 2025.
World J Clin Oncol. Apr 24, 2025; 16(4): 104827
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.104827
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.104827
Table 2 Detailed demographics and Baseline investigations of each patient (n = 10) recruited in the study
Sl. No. | Gender | Age | Height (cm) | Weight (kg) | Baseline investigations |
1 | Female | 67 | 172 | 58 | LFT: WNL; KFT: WNL |
2 | Female | 64 | 170 | 50 | NA |
3 | Female | 62 | 168 | 49 | LFT: WNL; KFT: WNL |
4 | Female | 66 | 165 | 52 | NA |
5 | Female | 61 | 171 | 60 | LFT: WNL; KFT: WNL |
6 | Female | 65 | 169 | 55 | LFT: WNL; KFT: WNL |
7 | Male | 80 | 175 | 60 | NA |
8 | Male | 66 | 173 | 64 | NA |
9 | Male | 69 | 172 | 57 | LFT: WNL; KFT: WNL |
10 | Male | 71 | 180 | 68 | NA |
- Citation: Chakraborty P, Borgohain M. Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series. World J Clin Oncol 2025; 16(4): 104827
- URL: https://www.wjgnet.com/2218-4333/full/v16/i4/104827.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i4.104827